Abstract 16P
Background
This study aimed to assess preferences of patients and healthcare practitioners (HCPs) regarding treatment attributes for early-stage triple-negative breast cancer (TNBC) in the Asia-Pacific region.
Methods
A discrete choice experiment (DCE) was conducted in Australia, Korea, Philippines, Japan, and Taiwan, with 115 patients who self-reported a diagnosis of early-stage TNBC and 86 HCPs. Key attributes relevant to TNBC treatment decision-making were verified through qualitative interviews with clinical experts. A D-efficient fractional-factorial design was employed to create 15 online choice sets with seven key attributes: disease-free/event-free survival (DFS/EFS), pathological complete response (pCR), chance of undergoing breast conserving surgery after receiving anticancer treatment, febrile neutropenia, peripheral sensory neuropathy, diarrhea, and irreversible endocrine-related adverse events (AEs) requiring lifelong medication. A mixed logit model was used to estimate preference weights for attribute levels, which were then used to compute the relative importance score (RIS) for each attribute.
Results
Median age of patients were 44.0 (interquartile range 38.0-56.5) years. 68% of patients were married, 77% had children, 40% employed full-time and 70% had a college degree. 46% of patients were diagnosed below the age of 40. Among the HCPs, 58% were medical oncologists and the remaining breast or general surgeons. PCR, DFS/EFS, and peripheral sensory neuropathy were the three most important attributes in both HCP and patient groups. pCR had the highest weighted preference among patients and HCPs (RIS, 28.46 and 32.86, respectively). In general, patients assigned greater weight to safety attributes compared to HCPs, while HCPs assigned more weight to efficacy attributes than patients. Surgeons assigned more weight for irreversible endocrine-related AEs than medical oncologists (RIS, 14.4 vs. 5.4).
Conclusions
Overall, patients and HCP preferences were aligned in ranking for efficacy and safety attributes tested. Differences in preferences within the regions were notable.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
IQVIA Solutions Asia Pte. Ltd.
Funding
MSD International GmbH, Singapore Branch.
Disclosure
J. Lai, Y. Antill, K.H. Jung, C. Shimizu, M.L. Abesamis Tiambeng: Financial Interests, Personal, Advisory Board: MSD. E.M. Tan, S. Qu: Financial Interests, Personal, Full or part-time Employment, IQVIA was commissioned to carry out this study.: IQVIA Asia Pacific. C. Spiteri, S.Y. Ihm, D. Hsu: Financial Interests, Personal, Full or part-time Employment: MSD. All other authors have declared no conflicts of interest.
Resources from the same session
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract